Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
insulin aspart + insulin lispro
- Development stage
- Unknown
- Lead developer
- Tonghua Dongbao
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Subcutaneous, Intravenous
01
Overview
This combination would theoretically involve two rapid-acting insulins, insulin aspart and insulin lispro, which are used to manage blood sugar levels in diabetes. Insulin aspart is found in NovoLog, while insulin lispro is found in Humalog. Both work by facilitating glucose uptake in cells, thus lowering blood glucose levels.
- Other names
- aspart insulin + lipro insulin
02
Targets
INSR (Insulin receptor)IGF-1R (Insulin-like growth factor 1 receptor)
Beyond the preview
Go deeper on insulin aspart + insulin lispro.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on insulin aspart + insulin lispro.